Newsroom
Follow us as we passionately pursue our goal of improving life for those with cancer.
Get the latest
-
AVEO Pharmaceuticals, Inc. to Present at the Canaccord Genuity 30th Annual Global Growth Conference
Download PDF CAMBRIDGE, Mass., Aug 05, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Canaccord Genuity 30th Annual Global Growth Conference on Thursday, August 12, 2010 at 8:30…
-
AVEO Pharmaceuticals to Present at Cancer Stem Cells & The Tumor Microenvironment Conference
Download PDF AVEO’s Patented Tivozanib Biomarker Highlighted as Part of IBC’s Drug Discovery & Development Week CAMBRIDGE, Mass., Aug 02, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Murray Robinson, Ph.D., senior vice president, translational medicine, is scheduled to present…
-
AVEO Reports Second Quarter 2010 Accomplishments and Financial Results
Download PDF Advancement of Innovative Pipeline; Achievement of Collaboration-Driven Milestone CAMBRIDGE, Mass., Jul 29, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended…
-
AVEO Pharmaceuticals, Inc. Announces Timing for Second Quarter 2010 Financial Results, Webcast and Conference Call
Download PDF CAMBRIDGE, Mass., Jul 22, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company’s second quarter ended June 30, 2010 will be released before the market opens on Thursday, July 29, 2010. The AVEO management…
-
AVEO Pharmaceuticals’ Human Response Platform(TM) and Proprietary Mouse Models Featured in Nature Reviews Cancer
Download PDF CAMBRIDGE, Mass., Jun 30, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the publication of a cover article in the current issue of Nature Reviews Cancer summarizing the recent development of improved preclinical modeling approaches to cancer drug development. Citing the…
-
AVEO Pharmaceuticals Added to Russell 2000(R) Index and S&P MidCap 400
Download PDF CAMBRIDGE, Mass., Jun 29, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company has been added to the Russell 2000(R) Index, as part of the annual reconstitution of the entire Russell family of indexes that took place…
-
AVEO Pharmaceuticals, Inc. Receives Orphan Medicinal Product Designation for Tivozanib for the Treatment of Renal Cell Carcinoma by the European Medicines Agency
Download PDF Designation Reinforces Opportunity for Safe and Effective Treatment Option for Renal Cell Cancer CAMBRIDGE, Mass., Jun 24, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received orphan medicinal product designation for tivozanib (N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N’-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate), its oral,…
-
AVEO Pharmaceuticals to Close NASDAQ Stock Market on June 22, 2010
Download PDF CAMBRIDGE, Mass., Jun 21, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Tuan Ha-Ngoc, president and chief executive officer of AVEO, will close the NASDAQ stock market on Tuesday, June 22, 2010. Members of the AVEO executive leadership team…
Follow us on social media
Media inquiries
For media inquiries, please contact:
John F. Kouten, CEO
JFK Communications, Inc.
jfkouten@jfkhealth.com
Direct: 609-241-7352
Download our media kit:
Meet our leadership team
The AVEO oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise with a proven track record for success in bringing important new therapies to patients.